Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZIMMER BIOMET HOLDINGS, INC.

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zimmer Biomet :  Biomet Announces First Quarter 2021 Financial Results

05/04/2021 | 06:37am EDT

345 E. Main St.

Warsaw, IN 46580

www.zimmerbiomet.com

Exhibit 99.1

Media

Investors

Meredith Weissman

Keri Mattox

(703) 346-3127

(215) 275-2431

meredith.weissman@zimmerbiomet.com

keri.mattox@zimmerbiomet.com

Ezgi Yagci

(617) 549-2443

ezgi.yagci@zimmerbiomet.com

Zimmer Biomet Announces

First Quarter 2021 Financial Results and Full Year Revenue Outlook

  • First quarter net sales of $1.847 billion increased 3.6%, 0.8% on a constant currency basis
  • First quarter diluted earnings per share were $0.94; adjusted diluted earnings per share were $1.71
  • Full-year2021 guidance provided - Company expects 14% to 17% revenue growth on a reported basis and 12.5% to 15.5% on a constant currency basis versus 2020

(WARSAW, IN) May 4, 2021 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2021. The Company reported first quarter net sales of $1.847 billion, an increase of 3.6% over the prior year period, and an increase of 0.8% on a constant currency basis. Net earnings for the first quarter were $198.1 million, or $359.1 million on an adjusted basis.

Diluted earnings per share were $0.94 for the first quarter. Adjusted diluted earnings per share were $1.71 for the first quarter, an increase of 0.6% over the prior year period.

"Our performance was stronger than we anticipated in the first quarter, as we saw signs of the pandemic beginning to subside across many regions toward the end of the quarter driven by acceleration of vaccine rollout. As we move into the second quarter, we expect that momentum to continue and believe we are well-positioned to meet the needs of our customers as elective procedures return," said Bryan Hanson, President and CEO of Zimmer Biomet. "Despite the challenges of COVID-19, the transformation of our business has continued over the past year. We are proud of the milestones Zimmer Biomet has already

Page 1 of 22

accomplished in 2021 and we have confidence that we can drive significant value for our key stakeholders as we move our Mission forward."

Please see the attached schedules accompanying this press release for additional details on performance in the quarter, including sales by Zimmer Biomet's three geographies and five product categories.

Recent Highlights

Aligned with Zimmer Biomet's active portfolio management strategy and the ongoing transformation of the business, key recent highlights include:

  • Introduction of ZBEdge, Zimmer Biomet's suite of integrated digital and robotic technologies, purposefully engineered to deliver data-powered clinical insights, shared seamlessly across the patient journey. ZBEdge includes the ROSA® Robotics Platform, anatomical visualization and guidance solutions such as Signature™ ONE Surgical Planning, remote care and patient engagement management systems like mymobility® with Apple Watch® , as well as data services and analytics including the OrthoIntel Orthopedic Intelligence Platform and the Omni™ Surgical Suite integrated operating room.
  • 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the ROSA® Partial Knee Systemfor robotically-assisted partial knee replacement surgeries, marking the latest addition to the ROSA program and the recently launched ZBEdge suite of integrated digital and robotic technologies.
  • Key additions to the Zimmer Biomet Leadership Team, including the appointments of the Company's first Chief Transformation Officer, Ellie Humphrey, and a new Chief Human Resources Officer, Lori Winkler, as well as the promotion of Sang Yi to Group President of APAC and the expansion of Ivan Tornos' role to Chief Operating Officer with new leadership responsibilities for the EMEA region.
  • Continued momentum for the planned spinoff transaction of the Spine & Dental businesses with the appointment of Vafa Jamalias President of "NewCo".

Geographic and Product Category Sales

In the three-month period ended March 31, 2021, the Company updated its product category sales reporting. Product category sales include the following changes:

Page 2 of 22

  • Orthopedic robotic capital sales and services, previously reported in the Knees product category, are included in the Other product category;
  • Disposable products used in computer-assisted surgeries, previously reported in the Other product category, are included in the Knees product category;
  • CMFT (Craniomaxillofacial and Thoracic) products, previously reported in the Dental, Spine & CMFT category, are included in the S.E.T. (Sports Medicine, Extremities and Trauma) product category;
  • CMFT has been removed from the Dental, Spine & CMFT product category and the name has been changed to Dental & Spine to reflect the revenue related to the planned spinoff of NewCo;
  • Office based technologies products, previously reported in the Other product category, are included in the Dental & Spine product category; and
  • Other immaterial adjustments across product categories related to brand alignment.

Prior period product category sales have been reclassified to conform to the current presentation. The Company has posted updated sales tables for fiscal 2020 and 2019 reflecting these changes on the Investor Relations section of its website, https://investor.zimmerbiomet.com. These changes have no impact on the Company's consolidated results of operations.

The following sales table provides results by geography and product category for the three-month period ended March 31, 2021, as well as the percentage change compared to the prior year period, on both a reported basis and a constant currency basis.

Page 3 of 22

NET SALES - THREE MONTHS ENDED MARCH 31, 2021

(in millions, unaudited)

Constant

Net

Currency

Sales

% Change

% Change

Geographic Results

Americas

$

1,115.0

1.2

%

1.0

%

EMEA

384.2

(3.5

)

(10.3

)

Asia Pacific

348.2

22.4

15.5

Total

$

1,847.4

3.6

%

0.8

%

Product Categories

Knees

Americas

$

358.8

(5.1)%

(5.4)%

EMEA

131.3

(14.0)

(19.8)

Asia Pacific

124.2

26.9

18.5

Total

614.3

(2.3)

(5.2)

Hips

Americas

235.2

1.1

0.9

EMEA

107.7

(3.2)

(9.5)

Asia Pacific

104.1

17.3

11.2

Total

447.0

3.3

0.3

S.E.T. *

417.6

9.6

7.2

Dental & Spine

246.0

12.1

9.6

Other

122.5

0.3

(2.5)

Total

$

1,847.4

3.6

%

0.8

%

* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic

Page 4 of 22

Financial Guidance

The Company is providing the following full-year 2021 financial guidance:

Projected Year Ending December 31, 2021

2021 reported revenue growth

14%

- 17%

Foreign Currency Exchange Impact

1.5%

Adjusted Operating Profit Margin(1)

26.5%

- 27.5%

Adjusted Tax Rate(1)

16.0%

- 16.5%

Adjusted Diluted EPS(1)

$7.60

- $8.00

These measures are non-GAAP financial measures for which a reconciliation to the

  1. most directly comparable GAAP financial measure is not available without unreasonable efforts. See "Forward-LookingNon-GAAP Financial Measures."

Conference Call

The Company will conduct its first quarter investor conference call today, May 4, 2021, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.comor follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Website Information

We routinely post important information for investors on our website, www.zimmerbiomet.com, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public

Page 5 of 22

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Zimmer Biomet Holdings Inc. published this content on 04 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 May 2021 10:36:01 UTC.


© Publicnow 2021
All news about ZIMMER BIOMET HOLDINGS, INC.
07/15BACTIGUARD : Interim report for Q2 2021
AQ
07/06ZIMMER BIOMET : Announces Webcast and Conference Call of Second Quarter 2021 Fin..
PR
07/01ZIMMER BIOMET : Makes Milestone Payment to Sweden's Bactiguard After Trauma Impl..
MT
06/30BACTIGUARD : receives payment from Zimmer Biomet
AQ
06/25ZIMMER BIOMET HOLDINGS, INC. : Ex-dividend day for
FA
06/15BACTIGUARD : coated Zimmer Biomet trauma implants for infection prevention launc..
AQ
06/10Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2021, Payabl..
CI
06/07Zimmer Biomet Holdings Names Chief Science, Technology and Innovation Officer
MT
06/07Zimmer Biomet Announces New Appointments to Executive Leadership Team
CI
06/03Zimmer Biomet Holdings Seeks Acquisitions
CI
More news
Financials (USD)
Sales 2021 8 115 M - -
Net income 2021 1 063 M - -
Net Debt 2021 6 229 M - -
P/E ratio 2021 32,1x
Yield 2021 0,59%
Capitalization 33 949 M 33 949 M -
EV / Sales 2021 4,95x
EV / Sales 2022 4,53x
Nbr of Employees 20 000
Free-Float 66,7%
Chart ZIMMER BIOMET HOLDINGS, INC.
Duration : Period :
Zimmer Biomet Holdings, Inc. Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 162,84 $
Average target price 190,46 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Bryan C. Hanson Chairman, President & Chief Executive Officer
Suketu P. Upadhyay Chief Financial Officer & Executive Vice President
Zeeshan Tariq Chief Information Officer & Senior Vice President
Nitin Goyal Chief Science, Technology & Innovation Officer
Ivan Tornos Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZIMMER BIOMET HOLDINGS, INC.5.68%33 949
ABBOTT LABORATORIES9.43%212 366
MEDTRONIC PLC11.17%172 114
BECTON, DICKINSON AND COMPANY1.79%72 539
HOYA CORPORATION5.22%50 566
ALIGN TECHNOLOGY, INC.17.05%50 298